Shares of Halyard Health Inc (NYSE:HYH) have been assigned an average recommendation of “Buy” from the eight brokerages that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $47.00.

HYH has been the subject of a number of research analyst reports. TheStreet cut shares of Halyard Health from a “b-” rating to a “c+” rating in a research report on Monday, October 30th. Zacks Investment Research raised shares of Halyard Health from a “hold” rating to a “buy” rating and set a $53.00 price objective for the company in a research report on Thursday, January 4th. ValuEngine raised shares of Halyard Health from a “hold” rating to a “buy” rating in a research report on Saturday, November 4th. KeyCorp reaffirmed a “hold” rating on shares of Halyard Health in a research report on Tuesday, October 17th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $52.00 price target on shares of Halyard Health in a research report on Friday, November 3rd.

A number of hedge funds have recently modified their holdings of HYH. Macquarie Group Ltd. purchased a new position in Halyard Health in the 3rd quarter valued at approximately $19,063,000. Koch Industries Inc. purchased a new position in Halyard Health in the 2nd quarter valued at approximately $297,000. Patten Group Inc. boosted its position in Halyard Health by 1,342.6% in the 3rd quarter. Patten Group Inc. now owns 281,112 shares of the medical instruments supplier’s stock valued at $877,000 after buying an additional 261,626 shares during the period. Dimensional Fund Advisors LP boosted its position in Halyard Health by 5.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,292,483 shares of the medical instruments supplier’s stock valued at $148,262,000 after buying an additional 159,434 shares during the period. Finally, Chicago Equity Partners LLC boosted its position in Halyard Health by 96.2% in the 3rd quarter. Chicago Equity Partners LLC now owns 272,704 shares of the medical instruments supplier’s stock valued at $12,280,000 after buying an additional 133,699 shares during the period. 89.34% of the stock is owned by institutional investors.

Halyard Health (NYSE:HYH) traded down $0.20 during trading hours on Friday, hitting $45.38. 346,758 shares of the company were exchanged, compared to its average volume of 306,593. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.13 and a quick ratio of 1.19. The stock has a market cap of $2,120.00, a PE ratio of 38.13, a P/E/G ratio of 2.39 and a beta of 1.71. Halyard Health has a 1 year low of $35.24 and a 1 year high of $50.99.

TRADEMARK VIOLATION WARNING: “Halyard Health Inc (HYH) Receives $47.00 Average PT from Analysts” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://theolympiareport.com/2018/02/11/halyard-health-inc-hyh-receives-47-00-average-pt-from-analysts.html.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.